IMA-201 is a gene-modified cell therapy commercialized by Immatics, with a leading Phase I program in Hepatocellular Carcinoma and Sarcomas. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of IMA-201’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for IMA-201 is expected to reach an annual total of $34 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

IMA-201 Overview

IMA-201 is under development for the treatment of solid tumors such as  hepatocellular carcinoma, ovarian cancer and subtypes of sarcoma. It is administered intravenously. The therapeutic candidate is based on XPRESIDENT and ACTengine platform. XPRESIDENT is a target discovery engine which identifies tumor-associated peptides (TUMAPs) / T-cell targets. ACTengine platform uses autologous T-cells which are genetically engineered to express T-cell receptors targeting MAGEA4 and MAGEA8. These cells are expanded ex-vivo and reinfused back into the patient.

It was under development for the treatment of squamous cell non-small cell lung cancer, bladder cancer and head and neck squamous cell carcinoma.

Immatics Overview

Immatics is a biopharmaceutical company focused on the development of T cell immunotherapies to fight against cancer. Immatics is headquartered in Tuebingen, Germany.

The company reported revenues of (Euro) EUR34.8 million for the fiscal year ended December 2021 (FY2021), an increase of 11.2% over FY2020. The operating loss of the company was EUR86.3 million in FY2021, compared to an operating loss of EUR69.7 million in FY2020. The net loss of the company was EUR93.3 million in FY2021, compared to a net loss of EUR211.3 million in FY2020. The company reported revenues of EUR15.1 million for the third quarter ended September 2022, a decrease of 12.5% over the previous quarter.

For a complete picture of IMA-201’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.